Firefly Neuroscience, INC 8-K filings

Firefly Neuroscience, Inc. announced that its stockholders approved significant amendments to its charter and long-term incentive plan at the 2026 annual meeting.

Firefly Neuroscience, Inc. announced a Securities Purchase Agreement for up to $1 million in gross proceeds through the sale of units, each comprising common stock and two types of warrants.

Firefly Neuroscience has completed an additional $8 million private placement, issuing 5.33 million units at $1.50 per unit.

Firefly Neuroscience, Inc. announced an initial $2.25 million private placement with accredited investors, including warrants and potential for an additional $18 million.

Firefly Neuroscience, Inc. announced an At-the-Market offering for up to $7.4 million and revised its CTO's compensation structure, replacing an automatic bonus with a discretionary one.

Firefly Neuroscience, Inc. exchanged existing warrants with higher exercise prices for new warrants at a significantly reduced exercise price of $0.50 per share, aiming to raise up to $400,000.

Firefly Neuroscience, Inc. announced the results of its 2025 Annual Meeting, with stockholders approving all presented proposals, including director elections, auditor ratification, and a significant increase in authorized shares.

Firefly Neuroscience, Inc. announced the termination of its $10 million equity line of credit agreement and an increase in its Chief Financial Officer's annual base salary.

Firefly Neuroscience, Inc. has completed a private placement, raising $1.2 million through the issuance of units comprising common stock or pre-funded warrants, alongside two types of common stock purchase warrants.

Firefly Neuroscience acquires Evoke Neuroscience to enhance its brain health solutions and build a proprietary foundation model of the human brain.

Firefly Neuroscience appoints David DeCaprio as President and COO, grants equity awards to executives, and settles disputes with investors and a former employee.

Firefly Neuroscience appoints Greg Lipschitz as CEO, outlining a three-year employment agreement with a $300,000 base salary, bonus potential, and stock options.

Greg Lipschitz resigns as Executive Chairman of Firefly Neuroscience, with Arun Menawat appointed as the new Chairman, effective immediately.

Firefly Neuroscience stockholders approved proposals related to the issuance of common stock to comply with Nasdaq listing rules at a special meeting held on February 14, 2025.

Firefly Neuroscience's CEO, Jon Olsen, resigned from the board and was subsequently removed from his CEO position, with Greg Lipschitz appointed as Interim CEO.

Firefly Neuroscience successfully held its annual meeting, electing three Class I directors, ratifying its auditor, and approving executive compensation on an advisory basis.

Firefly Neuroscience has entered into agreements for a $2.4 million convertible note and a $10 million equity line of credit, alongside issuing warrants and registering shares for resale.

Firefly Neuroscience has appointed Greg Lipschitz as Executive Chairman, effective December 3, 2024, replacing David Johnson who stepped down on November 30, 2024.

Firefly Neuroscience, Inc. reports the resignation of David Johnson as Executive Chairman and the appointment of Greg Lipschitz to the role, effective December 3, 2024.

Firefly Neuroscience announced its third quarter 2024 financial results, highlighting strategic partnerships and advancements in its AI-driven brain analysis technology.

Firefly Neuroscience has dismissed Turner, Stone & Company LLP and appointed Marcum Canada, LLP as its new independent registered public accounting firm.

Firefly Neuroscience has amended its previous 8-K filing to include the independent auditor's report and to restate details of a private placement that closed on August 12, 2024.

Firefly Neuroscience has appointed David Johnson as Executive Chairman and Stella Vnook as a new director, while also adjusting committee memberships and board classifications.

Firefly Neuroscience completed its reverse merger with WaveDancer, changed its name, and began trading on the Nasdaq Capital Market under the ticker symbol AIFF.

Firefly Neuroscience has finalized its merger with WaveDancer, Inc., and will commence trading on the Nasdaq under the ticker symbol AIFF on August 13, 2024.

WaveDancer, Inc. has entered into a securities purchase agreement to raise approximately $3.5 million through a private placement of common stock and warrants, coinciding with its merger with Firefly Neuroscience, Inc.

WaveDancer and Firefly Neuroscience have amended their merger agreement, extending the deadline to July 15, 2024, with a possible extension to August 15, 2024, and adjusting financial terms.

WaveDancer, Inc. has extended its line of credit maturity date with Summit Community Bank to July 16, 2024, by making principal payments and paying extension fees.

WaveDancer Inc. reports that CohnReznick LLP has resigned as their independent registered public accounting firm, effective May 16, 2024.

Firefly Neuroscience has appointed David Johnson as Executive Chairman, effective upon the closing of its merger with WaveDancer, Inc.